Tag:
Celldex Therapeutics
Latest Headlines
Latest Headlines
Promising glioblastoma data spur Celldex shares
Shares of Celldex Therapeutics shot up after a team of top researchers achieved prominent attention for some impressive mid-stage clinical trial results for a new therapeutic vaccine designed to
Pfizer returns brain cancer vax rights to Celldex
Pfizer is returning the rights to rindopepimut (CDX-110), a therapeutic cancer vaccine, to Celldex Therapeutics. Pfizer, which gained rights to the drug as part of $440 million deal in 2008, says
Vax for range of cancers may be available in 5 years
A vaccine that has shown to be effective against breast, bowel and cervical cancers is being tested on some patients and may be available in about five years. The vaccine, which is being developed by
The ASCO roundup: ArQule drug flunks a mid-stage test
Plenty of more early-stage and mid-stage study results came to light at ASCO over the past day. Here are some of the highlights: ArQule said that its lung cancer drug flunked a mid-stage study, but
ASCO: Lilly tracks partial melanoma response, Celldex shares sink
Last night's data dump ahead of ASCO produced a treasure trove of information, but few signs of any dramatic leap or pratfall. Among the highlights: Eli Lilly (NYSE: LLY) reported that a handful of
Cancer vax developers' shares spike on data
Shares of Antigenics surged for three straight days this week after researchers released new data backing its kidney cancer vaccine Oncophage. Investors pushed the stock straight up after hearing
Celldex acquires CuraGen for $94.5M
Massachusetts-based Celldex Therapeutics is paying $94.5 million to acquire CuraGen. Celldex gains CuraGen's portfolio of 11 oncology-focused antibodies. Its most advanced therapy is CR011, which is
Vaccines Technologies, Celldex ink deal
Boston-based Vaccine Technologies (VTI) has inked a license and development agreement with Celldex Therapeutics. VTI will have exclusive licensing rights to Celldex's CholeraGarde and ETEC vaccine
Celldex inks tech deal to advance cancer vaccines
Celldex Therapeutics has struck a deal to use 3M's toll-like receptor (TLR) agonist compounds--useful as vaccine adjuvants--for a slate of new oncology vaccines in development. 3M Drug Delivery
Pfizer, Avant ink $440M cancer vax deal
Avant Immunotherapeutics is pocketing a $40 million upfront fee and a $10 million equity stake from Pfizer in exchange for the worldwide rights to Avant's experimental brain cancer vaccine. And
